1-9 of 9
Andrew Garton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection

Vinu Menon, Lida Pacaud, Beata Holkova, Sunitha Gn, Andrew Garton, Maria Pihlgren, Tomomi Matsuura, Piet H van der Graft, Mario Perro, Cyril Konto
Journal: Blood
Blood (2024) 144 (Supplement 1): 6854.
https://doi.org/10.1182/blood-2024-209580
Published: 2024
Journal Articles

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I Lichtman, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot
Journal: Blood
Blood (2024) 144 (Supplement 1): 1026.
https://doi.org/10.1182/blood-2024-208189
Published: 2024
Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3364.
https://doi.org/10.1182/blood-2024-209952
Published: 2024
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Vinu Menon, Andrew Garton, Eileen Wolff, Tejas Shah, Colleen Charpentier, Dominique Duchesne, Maria Pihlgren, Jeppe Koch-Olsen, Adam Drake, Mario Perro, Eugene Zhukovsky, Lida Pacaud, Cyril Konto
Journal: Blood
Blood (2023) 142 (Supplement 1): 3396.
https://doi.org/10.1182/blood-2023-187106
Published: 2023
Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Dickran Kazandjian, Hang Quach, Hanlon Sia, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Binod Dhakal, Tara Cochrane, Jeffrey A. Zonder, Nancy Yi, Dominique Duchesne, Tejas Shah, Andrew Garton, Vinu Menon, Sunitha Gn, Stefano Sammicheli, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Peter Tan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4707.
https://doi.org/10.1182/blood-2023-186241
Published: 2023
Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Sanjay R Mohan, Cristiana Costa Chase, Jesus G Berdeja, Lionel Karlin, Karim Belhadj, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Thomas Chalopin, Alexander M Lesokhin, Carol Ann Huff, David H. Vesole, Joshua Richter, Jeffrey V. Matous, Igor Proscurshim, Eileen Wolff, Girish Gudi, Andrew Garton, Vinu Menon, Sunitha Gn, Yacine Salhi, Eric J. Feldman, Mohamad Mohty
Journal: Blood
Blood (2022) 140 (Supplement 1): 7264–7266.
https://doi.org/10.1182/blood-2022-157525
Published: 2022
Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10182–10184.
https://doi.org/10.1182/blood-2022-157585
Published: 2022
Journal Articles

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, MD, Daniel J. DeAngelo, MD PhD, David A. Sallman, MD, Monica L. Guzman, PhD, Pinkal Desai, MDMPH, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Francisco Javier Esteva, MD PhD, Andrew Garton, Kate Backhouse, Roman Galetto, PhD, Carrie Brownstein, MD, Naveen Pemmaraju, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-138984
Published: 2020